Q4 2016 13F Holders as of 12/31/2016
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
51
-
Total 13F shares, excl. options
-
35.9M
-
Shares change
-
+2.6M
-
Total reported value, excl. options
-
$88.2M
-
Value change
-
+$3.85M
-
Put/Call ratio
-
8.41
-
Number of buys
-
34
-
Number of sells
-
-19
-
Price
-
$2.45
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q4 2016
64 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q4 2016.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 51 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.9M shares
of 193M outstanding shares and own 18.57% of the company stock.
Largest 10 shareholders include QVT Financial LP (16M shares), LADENBURG THALMANN FINANCIAL SERVICES INC. (5.29M shares), PRIMECAP MANAGEMENT CO/CA/ (3.94M shares), ARMISTICE CAPITAL, LLC (1.94M shares), D. E. Shaw & Co., Inc. (1.73M shares), Falcon Edge Capital LP (1.66M shares), BANK OF MONTREAL /CAN/ (885K shares), AXA (808K shares), SABBY MANAGEMENT, LLC (793K shares), and K2 PRINCIPAL FUND, L.P. (444K shares).
This table shows the top 51 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.